Previous unpublished attempts using S. cerevisiae Gal4p DBD (residues 1-147, henceforth termed GAL4 SC ) with human herpes virus activation domain (VP16) 3 as the driver components exhibited poor performance in C. elegans. Since stronger activation domains improve performance of the GAL4 driver 4 , we tested VP64 (ref. 5 ), which has four tandem copies of VP16. We fused GAL4 SC to VP16 and VP64 and placed them both under the pharyngeal muscle promoter (Pmyo-2), designating them Pmyo-2::GAL4 SC ::VP16 and Pmyo-2::GAL4 SC ::VP64, respectively. Comparing their performance in a 15xUAS::gfp effector transgene strain (syIs300), the Pmyo-2::GAL4 SC ::VP64 driver yielded seven-fold more GFP fluorescence in pharyngeal muscles at room temperature (Fig. 1b,c) than did Pmyo-2::GAL4 SC ::VP16. The fluorescence observed requires both driver and effector transgenes ( Supplementary Fig. 1) . We therefore adopted VP64 as our activation domain.
We optimized UAS copy number by comparing constructs with 5×, 10×, 15× and 20× UAS copies upstream of gfp at equal concentrations in a strain with a Pmyo-2::GAL4 SC ::VP64 driver (syIs301). We found successively increasing GFP fluorescence until 15× UAS copies (~2.3-fold versus 5× UAS, P < 0.0001; ~1.3-fold versus 10× UAS, P < 0.01, one-way ANOVA, Tukey's post-test), beyond which it appeared to saturate (~1.1-fold versus 20× UAS, P = 0.5, one-way ANOVA, Tukey's post-test; Fig. 1d,e ). Thus, 15× UAS was adopted for effector constructs.
To determine the robustness of our GAL4-UAS system under standard C. elegans growth temperatures (15-25 °C), we assayed our Pmyo-2::GAL4 SC ::VP64 driver and 15xUAS::gfp effector combination, and we found its transcriptional efficacy depended heavily on temperature; it performed well only at 25 °C ( Fig. 2a,b ; ~67% decrease in fluorescence at 20 °C, ~80% decrease in fluorescence at 15 °C, P < 0.0001, two-way ANOVA with Tukey's correction), consistent with findings in Drosophila 6 .
The temperature dependence of the canonical GAL4-UAS system and the optimal growth temperature of S. cerevisiae (30-34 °C) 6, 7 suggested that activity of Gal4p from a specific yeast species may be adapted to its optimal growth temperature. Thus, a Gal4p from more cryophilic Saccharomyces yeast species might prove useful in designing a more robust driver at lower temperatures. We chose the Gal4p DBD from Saccharomyces kudriavzevii 8 (Portuguese reference strain ZP591, residues 1-147, henceforth termed GAL4 SK ) because S. kudriavzevii has an optimal growth temperature (23-24 °C) 7 close to that of C. elegans, and the key residues necessary for UAS binding 9 are conserved between GAL4 SC and GAL4 SK (Fig. 2c) .
We generated a new Pmyo-2 driver by replacing GAL4 SC with GAL4 SK , and we compared this driver's performance with that the GaL4-uas system is a powerful tool for manipulating gene expression, but its application in Caenorhabditis elegans has not been described. here we systematically optimize the system's three main components to develop a temperatureoptimized GaL4-uas system (cGaL) that robustly controls gene expression in C. elegans from 15 to 25 °c. We demonstrate this system's utility in transcriptional reporter analysis, site-ofaction experiments and exogenous transgene expression; and we provide a basic driver and effector toolkit.
Bipartite gene expression systems offer fine spatial and temporal control of gene expression, and they are crucial for understanding gene function. The GAL4-UAS system, which has proven highly useful in Drosophila studies 1 , uses the Saccharomyces cerevisiae Gal4p protein, which contains a DNA-binding domain (DBD) and a transcriptional activation domain (AD). Gal4p homodimers bind a 17-nucleotide upstream activating sequence (UAS), resulting in transcription of a downstream gene 2 . Cell-specific promoters placed upstream of GAL4 constitute a 'driver' construct, while UAS sites placed upstream of the gene of interest constitute an 'effector' construct. Incorporation of these constructs into separate transgenics creates standardized driver and effector lines, which can be crossed together, generating progeny with desired expression patterns (Fig. 1a) .
The bipartite nature of GAL4-UAS offers three major advantages over direct promoter-gene fusions. Large numbers of strains can easily be generated by crossing driver and effector lines. Incorporating novel components into pre-existing driver and effector libraries requires minimal effort. Verified driver and effector strains become community reagents that foster experimental consistency and reproducibility. However, the GAL4-UAS system has not been successfully adapted for use in C. elegans. We optimized three components of the GAL4-UAS system to make it functional for C. elegans across 15-25 °C, and we demonstrated its robustness for tissue-specific gene expression, sitespecific genetic rescue and channelrhodopsin experiments. of the GAL4 SC driver across 15-25 °C using the same integrated 15xUAS::gfp effector strain (syIs300). The Pmyo-2::GAL4 SK ::VP64 driver lines exhibited more fluorescence than did the Pmyo-2:: GAL4 SC ::VP64 driver lines at room temperature; blinded researchers accurately sorted these two drivers using an epifluorescence dissecting microscope. We chose the brightest line from each driver for quantitation. At all temperatures, the Pmyo-2::GAL4 SK ::VP64 driver performed more robustly than the Pmyo-2::GAL4 SC ::VP64 driver; a performance in some instances comparable to that of strains carrying a direct Pmyo-2::gfp fusion as a benchmark ( Fig. 2b and Supplementary Fig. 2 ). Our GAL4 SK driver had slightly higher fluorescence at 25 °C ( Fig. 2a,b ) and exhibited only an ~20% decrease in fluorescence at 20 °C (versus ~67% for GAL4 SC ) and only an ~40% decrease in fluorescence at 15 °C (versus ~80% for GAL4 SC ). We adopted GAL4 SK as our DBD of choice, in conjunction with VP64 and 15× UAS, to comprise our fully optimized GAL4-UAS system. We designated our system cGAL to denote its original implementation in C. elegans and its engineered performance at cooler temperatures.
We tested whether cGAL would perform in other major tissues by generating new driver constructs containing various tissue-specific promoters (Pnlp-40, intestine; Pmyo-3, body wall muscles). When injected into a strain (syIs300) with an integrated 15xUAS:: gfp effector, these new drivers produced robust and specific GFP fluorescence in expected tissues ( Fig. 3a,b ). However, our initial pan-neuronal (Prab-3) and GABAergic (Punc-47) drivers displayed poor, mosaic expression in the nervous system along with intense ectopic GFP fluorescence in the posterior gut (data not shown). We speculated that our vector backbone (a derivative of pPD49.26 containing the unc-54 3′ UTR) might be responsible. We therefore switched to the vector pPD117.01 containing the let-858 3′ UTR and a 5′ decoy sequence (comprising a decoy intron and open reading frame) upstream of the multiple cloning sites (see Online Methods and Supplementary Notes 1 and 2); these modifications reduce ectopic expression and improve expression in a broad range of tissues (A. Fire, personal communication). We generated new Prab-3 and Punc-47 driver constructs in the pPD117.01 backbone and injected them into a strain (syIs390) with a new 15xUAS::gfp::let-858 3′UTR effector (also made using pPD117.01; Supplementary Notes 3 and 4) . These strains not only showed decreased ectopic fluorescence in the posterior gut (data not shown), but also displayed dramatically increased fluorescence in the entire nervous system (Fig. 3c) or GABAergic neurons (Fig. 3d) . Cholinergic (Punc-17) and glutamatergic (Peat-4) neuronal drivers gave similarly strong and specific results in the syIs390 effector strain (Fig. 3e,f) . Thus, cGAL is robust across a variety of tissues, and we recommend using the pPD117.01 vector for driver and effector construction. We then applied cGAL to functional studies by examining the rhythmic defecation motor program (DMP), which contains three sequential muscle contractions 10 . The final enteric muscle contraction occurs when the intestine releases neuropeptide NLP-40, which binds its receptor AEX-2 on GABAergic neurons, triggering an expulsion event 11, 12 (Fig. 3g) . We applied cGAL to confirm the site-of-action of aex-2 in GABAergic neurons for expulsion. We generated an effector line (syEx1444) with 15xUAS:: aex-2(+) cDNA in the aex-2(sa3) background. This strain was then combined with a Pnlp-40 driver, Punc-47 driver or Pmyo-3 driver to create aex-2(sa3) mutants expressing aex-2(+) cDNA specifically in the intestine, GABAergic neurons or body wall muscles, respectively.
In aex-2(sa3) mutants, expulsion was nearly eliminated. Only the presence of both GABAergic driver and 15xUAS::aex-2(+) cDNA effector rescued the expulsion defect of aex-2(sa3) mutants; neither could rescue the defect alone (Fig. 3h) . Expression of aex-2(+) cDNA in either body wall muscles or intestine did not rescue (Fig. 3h) . These results recapitulate a study using conventional promoter-cDNA fusion transgenes 12 . Therefore, cGAL can be used for tissue-specific rescue experiments.
Next, we tested whether cGAL could be applied to gain-offunction experiments. Channelrhodopsin is a light-sensitive cation channel that depolarizes cells in the presence of all-trans retinal and blue light 13 . Activation of GABAergic neurons in C. elegans causes worms to adopt a flaccid, paralyzed state. We injected the GABAergic driver construct into a strain (syIs341) carrying an integrated 15xUAS::hChR2(H134R)::eyfp::let-858 3′UTR effector to express channelrhodopsin specifically in GABAergic neurons. In the presence of all-trans retinal, animals were subjected to a three-pulse train of 475-nm blue light. Each excitation caused immediate, limp paralysis only in animals possessing both GABAergic driver and effector but not in animals with either component alone ( Fig. 3i, Supplementary  Videos 1 and 2, and data not shown) . cGAL is thus capable of controlling exogenous transgene expression to interrogate neural circuits in C. elegans.
Finally, we built a basic cGAL driver and effector toolkit (Supplementary Tables 1 and 2) . For drivers, we constructed strains and plasmids for major tissues, major neurotransmitter cell types and some individual sensory neurons. For effectors, we have integrated strains for cell labeling (GFP, mKate2, GFP-H2B and mCherry-H2B), cell ablation (ICE), calcium sensing (GCaMP6s), neuronal activation (ChR2), neuronal inhibition (HisCl1) and synaptic inhibition (TeTx). All effectors are integrated, and at least one line for each integrated effector was confirmed to be functional ( Supplementary Fig. 3 and Supplementary Videos 1-5).
One limitation of cGAL is the absence of Gal80p, a negative regulatory component used to repress Gal4p as a 'NOT' gate 14 .
Gal80p recognizes the C terminus of Gal4p 15 , absent in our drivers. Addition of the minimal C-terminal functional domain that interacts with S. kudriavzevii Gal80p might address this issue.
A similar bipartite expression system, Q 16 , has yet to be widely adopted in C. elegans, perhaps because of lack of sufficient drivers and effectors. As with Drosophila 1,17 , the cGAL system could be combined with Q or other binary expression systems 16, [18] [19] [20] for control of multiple effectors.
cGAL can already facilitate genetic site-of-action and genomewide overexpression experiments, but we envision that a growing collection of drivers and effectors will allow analysis of genetic, developmental and neural networks with increased rate and rigor.
methods
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
acknoWLedGments
We are grateful to A. Fire (Stanford University) for sharing unpublished results and to C.T. Hittinger (University of Wisconsin-Madison), D. Sieburth (University of Southern California), E.M. Jorgensen (University of Utah), C. Bargmann (Rockefeller University) and A. Fire (Stanford University) for reagents. We thank H. Korswagen (Hubrecht Institute) for thoughtful discussion. N.P. thanks C. Bargmann for her support. We thank M. Bao, Y.M. Kim, D. Leighton, J. DeModena and G. Medina for technical assistance; and WormBase for technical support. We also thank M. Kato, H. Schwartz, D. Angeles-Albores and other members of the Sternberg lab for editorial comments on the manuscript. Some strains were provided by the CGC, which is funded by the NIH Office of Research Infrastructure Programs (grant P40 OD010440). Some imaging was performed at the Caltech Biological Imaging Facility with the support of the Caltech Beckman Institute and the Arnold and Mabel Beckman Foundation. H.W. is supported by the Della Martin Fellowship. J.L. was supported by NIH grant T32GM007616. This work is supported by the Howard Hughes Medical Institute, with which P.W.S. is an investigator. author contributions H.W., J.L. and P.W.S. conceived the project. H.W. and J.L. performed the experiments, analyzed the data and wrote the paper. S.G. helped with molecular cloning and strain handling. E.M.S. devised the idea of trying Gal4p from yeast species with lower growth temperatures. C.M.C. and N.P. contributed reagents.
